What is it about?

This review article describes and discusses the major therapeutic strategies to activate the endocannabinoid system beyond the direct activation of cannabinoid receptors. This endogenous system plays a key role in the brain and its dysregulation has been reported in many neuropsychiatric disorders such as depression, anxiety, chronic stress, post-traumatic stress disorders, schizophrenia. The most important molecules developed as tool compounds and drug candidates in pre-clinical and clinical phase of development are reviewed.

Featured Image

Why is it important?

The ongoing debate about the medical use of cannabis and its major component delta-9-tetraydrocannabinol can be overcome by the development of novel pharmacological approaches that maintain the positive effects without leading to the adverse events in the brain. This article represents an up-to-date summary of the current and future therapeutic strategies to modulate the endocannabinoid system. The authors discuss the pros and cons of each of these strategies and present major the compounds for each pharmacological class that have been tested in pre-clinical and clinical phase.

Read the Original

This page is a summary of: Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases, Recent Patents on CNS Drug Discovery, September 2016, Bentham Science Publishers,
DOI: 10.2174/1574889810999160603185126.
You can read the full text:

Read

Contributors

The following have contributed to this page